A method for analyzing protein-small molecule ligand interactions based on time-resolved fluorescence resonance energy transfer
Through the analysis method based on time-resolved fluorescence resonance energy transfer, the protein-small molecule interaction model was analyzed, the problem of insufficient information in the existing technology was solved, the support for PROTAC drug development was improved, and the target protein and E3 ubiquitin was promoted. Understanding of ligase interactions.
Patent Information
- Application Number
- CN202410131821.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-31
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-01-31
AI Technical Summary
The limited information obtained by the prior art in analyzing protein-small molecule interactions is restricted by the discovery and structural optimization of high affinity ligands, especially in the development of PROTAC drugs, the interaction mode of target protein and E3 ubiquitin ligase. Inadequate understanding.
Using an analysis method based on time-resolved fluorescence resonance energy transfer, the terbium complex is used as the FRET donor and the small molecule fluorescent dye Cy5 as the FRET acceptor, and the fluorescence lifetime information is obtained through the fluorescence decay curve fitting, and the FRET efficiency and donor acceptor are calculated. By actual distance, PROTAC simulates the interaction process between target protein and small molecule ligand, and then analyzes the interaction mode of protein-small molecule.
It improves the understanding of protein-small molecule interactions, provides more accurate binding parameters and interaction patterns, helps accelerate the development of PROTAC drugs, and improves the understanding of the mechanism of action of target proteins and E3 ubiquitin ligase.
Smart Images

Figure CN118050337B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biochemical analysis and detection, and specifically relates to a protein-small molecule ligand interaction analysis method based on time-resolved fluorescence resonance energy transfer. Background Art
[0002] In traditional targeted protein drug design, drugs need to bind to specific sites or "pockets" in proteins to inhibit / activate the biological functions of proteins, while nearly 85% of proteins do not have binding sites suitable for small molecule drugs, resulting in poor drugability of these proteins. Targeted protein degradation (TPD) is an emerging drug mode of action that uses the cell's protein balance system to induce the degradation of target proteins. In 2001, proteolysis-targeting chimeras (PROTACT) were first proposed as a chemical biology method and a new treatment method. It is an emerging drug therapy strategy based on target protein degradation that is closely related to the ubiquitination process. It has the characteristics of low dosage, low toxicity, the ability to target traditional undruggable targets, and long-lasting efficacy. PROTAC drugs generally consist of three parts: a linker molecule, a ligand that connects to the target protein, and a ligand that recruits the E3 ubiquitin ligase. The general way in which drugs work is that PROTAC specifically binds to the target protein and E3 ubiquitin ligase; ternary complexes are formed; ubiquitin system enzymes such as E1 / E2 / E3 are recruited; target proteins are ubiquitinated; and target proteins are degraded by the protease system. In recent years, more and more traditionally undruggable targets have been found to be PROTAC drug targets, but their development also faces many bottlenecks. For example, there are more than 600 E3 ligases in the human proteome, but the current development of PROTACs relies only on a few E3 ligases with known ligands, such as the E3 ubiquitin ligases Von Hippel-Lindau (VHL) and cereblon (CRBN). Due to the lack of understanding of the protein-small molecule interaction mechanism, PROTAC molecules designed with novel target protein ligands and E3 ubiquitin ligase ligands usually have poor degradation activity. Therefore, it is particularly important to analyze the interaction pattern of PROTAC warheads with target proteins and E3 ubiquitin ligases.
[0003] Compound-protein interaction (CPI) is a key issue in the drug development process. Currently, a variety of biophysical or biochemical analytical test methods are used to analyze its action characteristics, such as Western Blot (WB), Enzyme linked immunosorbent assay (ELISA), Surface Plasmon Resonance (SPR), Fluorescence polarization (FP), Time-resolved fluorescence resonance energy transfer (TRFE), and so on. resonance energy transfer (TR-FRET), etc. TR-FRET has the characteristics of high throughput, simple operation, no need for washing and separation, and is widely used in the activity screening of PROTAC drugs at the molecular and cellular levels, such as high-throughput screening of protein ligands through changes in the fluorescence intensity of the donor and acceptor in the FRET system, quantitative analysis of target proteins, and characterization of the target protein-PROTAC molecule-E3 ligase ternary complex. Although the analysis of protein-small molecule interactions is crucial, the interaction information obtained by existing methods is limited, which restricts the discovery and structural optimization of high-affinity ligands. Summary of the invention
[0004] The purpose of the present invention is to provide a protein-small molecule interaction analysis method based on time-resolved fluorescence resonance energy transfer. The method uses a terbium complex with a long fluorescence lifetime as a FRET donor and a small molecule fluorescent dye Cy5 as a FRET acceptor, and obtains fluorescence lifetime information by fitting the fluorescence decay curve of the FRET donor and acceptor, calculates the FRET efficiency and the actual distance of the donor and acceptor, and realizes the analysis of the interaction process between the PROTAC simulated target protein and its small molecule ligand, and then analyzes the interaction mode of the protein-small molecule, providing theoretical support for PROTAC drug development.
[0005] In order to achieve the above-mentioned invention object, the present invention adopts the following technical solutions:
[0006] The present invention provides a protein-small molecule interaction analysis method based on time-resolved fluorescence resonance energy transfer, and the analysis method specifically comprises the following steps:
[0007] (1) Fluorescently label the PROTAC-mimicking target protein with FRET donor and acceptor fluorophores, and perform protein purification and spectral property characterization;
[0008] (2) Co-incubating the fluorescently labeled PROTAC mimicking target protein with the fluorescent derivatization reagent of its small molecule ligand to form a FRET system; exciting with the excitation wavelength of the fluorescent donor, collecting the fluorescence decay curve of the donor and acceptor in the FRET system, and fitting the fluorescence decay curve;
[0009] (3) Analyze spectral data, calculate the binding parameters of protein-small molecule interactions, and obtain the results of protein-small molecule interaction pattern analysis.
[0010] Furthermore: the simulated target proteins in step (1) are Halo Tag and E3 ubiquitin ligase CDC20.
[0011] Further: In the step (1), the PROTAC mimic target protein Halo Tag is labeled with the FRET acceptor fluorophore Cy5-NHS ester, and the E3 ubiquitin ligase CDC20 protein is labeled with the FRET donor fluorophore CoraFluor-1free acid Tb.
[0012] Furthermore, the PROTAC simulates the labeling of the target protein Halo Tag by randomly labeling the receptor fluorophore Cy5-NHSester on the free amino groups on the surface of the simulated target protein Halo Tag.
[0013] Furthermore, the labeling of the E3 ubiquitin ligase CDC20 protein is to randomly label the donor fluorophore CoraFluor-1free acid (Tb) on the free amino groups on the surface of the E3 ubiquitin ligase CDC20 protein.
[0014] Furthermore: in the step (2), the fluorescent derivatization reagents of the small molecule ligands of the PROTAC mimicking target protein Halo Tag and E3 ubiquitin ligase CDC20 protein are Halo Tag ligand-Tb and Apcin-Cy5, respectively.
[0015] Further, the cells were incubated at 37°C for 60 min.
[0016] Further: the spectral data analysis in step (3) is performed by using multi-channel scanning, by measuring the fluorescence decay curve of the donor and the acceptor in the FRET system, counting the total number of photons of the donor and the acceptor in a certain time window, and calculating the FRET ratio by the ratio of the fluorescence intensity of the donor and the acceptor; using the unit site-total binding fitting model in Prism8 to calculate the dissociation constant Kd; by fitting the fluorescence decay curve of the donor and the acceptor, the FRET efficiency E in the presence of different concentrations of the acceptor is calculated. FRET And the change of FRET distance r is used to analyze the protein-small molecule interaction mode.
[0017] The FRET probability and FRET efficiency E are calculated by the amplitude A and decay time τ of the fluorescence decay curve. FRET FRET parameters such as the FRET distance r can be used to distinguish between static FRET caused by concentration dependence and dynamic FRET caused by distance changes.
[0018] Further: the fluorescence decay curve is fitted using a multi-exponential intensity decay function:
[0019]
[0020] Where I is the fluorescence intensity, A i is the amplitude corresponding to different fluorescence lifetimes, τ i is the fluorescence lifetime, t is the decay time, a i is the amplitude ratio of different fluorescence lifetimes.
[0021] Further: The calculation formula of the FRET distance r is as follows:
[0022]
[0023] Where R0 is the Distance is E FRET The distance between the donor and the receptor when it is equal to 50%, τ D is the fluorescence lifetime of the donor when the donor exists alone, <τ DA > is the average fluorescence lifetime of the donor in the presence of the acceptor, <τ AD > is the average fluorescence lifetime of the acceptor in the presence of the donor.
[0024] Further: The FRET efficiency E FRET The calculation formula is as follows:
[0025]
[0026] Furthermore: In the step (3), when there are different concentrations of fluorescently labeled PROTAC simulated target proteins, the FRET distance and FRET efficiency do not change significantly with the increase in the concentration of the simulated target protein, that is, the change in FRET distance is within ±5%, and the change in FRET efficiency is within ±10%. At this time, FRET exhibits ligand concentration-dependent static FRET with unchanged FRET efficiency and FRET distance.
[0027] Furthermore: in the step (3), when there is a low concentration of fluorescently labeled small molecules, the FRET distance and FRET efficiency remain almost unchanged, and the FRET system exhibits concentration-dependent static FRET; as the concentration of the small molecules increases, the FRET distance shows a significant downward trend, while the FRET efficiency shows a significant upward trend, and the FRET system exhibits distance-dependent dynamic FRET in which the FRET distance and efficiency change.
[0028] Further, in the Tb-to-Cy5 FRET system of the present invention, The distance (R0) is 5.5 nm. Since the effective working distance of FRET is between 0.5-2R0, the effective working distance of Tb-to-Cy5 FRET is 2.8-11 nm.
[0029] Compared with the prior art, the present invention has the following beneficial effects:
[0030] 1. The present invention detects by collecting in vitro FRET fluorescence signals, which is sensitive and rapid;
[0031] 2. The present invention uses the long fluorescence lifetime dye CoraFluor-1free acid (Tb) as the fluorescence donor, which has unique advantages such as good stability, narrow emission spectrum and large Stoke's shift, effectively reducing the detection background and improving the signal-to-noise ratio.
[0032] 3. The present invention measures the fluorescence decay curve of the fluorescent donor and acceptor and fits its fluorescence lifetime to calculate the distance change during the protein-small molecule interaction process, and then analyzes the protein-small molecule interaction mode, thereby improving the understanding of the PROTAC warhead recruitment target protein and E3 ubiquitin ligase mechanism. The present invention uses multi-channel scanning to measure the fluorescence decay curve of the donor and acceptor, calculates the binding affinity of the PROTAC simulated target protein Halo Tag and E3 ubiquitin ligase CDC20 with small molecule ligands, as well as FRET efficiency, FRET distance and other information, analyzes its interaction process, improves the understanding of the protein-small molecule interaction process, and helps to better understand the interaction mode between the target protein and E3 ubiquitin ligase and PROTAC during the formation of the ternary complex, provides a reference for PROTAC drug design, and accelerates the research and development process of PROTAC drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] The accompanying drawings constituting a part of the present invention are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the accompanying drawings:
[0034] Figure 1 It is a schematic diagram of the principle of the present invention;
[0035] Figure 2 The fluorescence labeling images of the target protein Halo Tag simulated by Cy5-NHS ester and the E3 ubiquitin ligase CDC20 protein by CoraFluor-1free acid (Tb) described in Examples 1 and 2 are shown;
[0036] Figure 3 To implement the analysis of the interaction mode between the simulated target protein Halo Tag and its small molecule ligand Halo Tag ligand-Tb as described in Case 3;
[0037] Figure 4 To analyze the interaction pattern between the E3 ubiquitin ligase CDC20 protein and its small molecule ligand Apcin-Cy5 described in implementation case 4. DETAILED DESCRIPTION
[0038] The present invention is further described in detail below in conjunction with the accompanying drawings and specific examples of the specification. The examples are only used to explain the present invention and are not used to limit the scope of the present invention. The test methods used in the following examples are conventional methods unless otherwise specified; the materials and reagents used are reagents and materials that can be obtained from commercial channels unless otherwise specified.
[0039] Example 1: Fluorescence labeling and spectral property characterization of Cy5-NHS ester simulating target protein Halo Tag
[0040] Succinimidyl ester (NHS ester) is a common coupling group that can react with amino groups under physiological to weakly alkaline conditions (pH7.5 to 9.5), so it is often used to label proteins. In this embodiment, Cy5 NHS ester was used to derivatize and label the amino groups of Halo Tag protein. First, a 0.5mL, 7kDa centrifugal desalting column was used to replace the protein storage solution and purify the free dye. The Halo Tag protein was mixed with Cy5-NHS ester (10mM, DMF) fluorescent dye in a ratio of 1: 1, incubated overnight at 4°C, and then the free dye was removed using a desalting column, and the labeled Halo Tag-Cy5 was stored in a storage buffer (20mM Tris, 50mM NaCl, pH 7.4).
[0041] The spectral properties of the labeled protein derivatized product Halo Tag-Cy5 are characterized as follows Figure 2As shown in A, the absorption spectra of HaloTag-Cy5 (blue line) and Cy5-NHS ester (red line), the concentrations of protein and Cy5 were calculated by the absorbance values of Halo Tag at a wavelength of 280nm and Cy5-NHS ester at a wavelength of 650nm, respectively, and the labeling ratio was obtained. The labeling ratio Halo Tag:Cy5 is 1:0.5.
[0042] Example 2: CoraFluor-1 free acid (Tb) fluorescent labeling and spectral characterization of E3 ubiquitin ligase CDC20 protein
[0043] Cell division cycle protein 20 (CDC20), a novel E3 ligase, was selected as the E3 ligase model molecule for analytical method construction.
[0044] The coupling of CoraFluor-1free acid (Tb) and CDC20 was carried out by EDC and NHS coupling agent method. The final concentration of 5mM EDC, 3.75mM NHS, and 15μM CoraFluor-1free acid (Tb) were placed in 25μL PBS solution with pH = 7.4, and the reaction was vigorously shaken for 2h, and then 75μL CDC20 protein with a final concentration of 10μM was added, and the reaction was carried out at room temperature for 4h. The protein storage solution was replaced with a 0.5mL, 7kDa centrifugal desalting column to remove free Tb.
[0045] The spectroscopic properties of CDC20-Tb are characterized as follows Figure 2 As shown in B, the absorption spectra of CDC20-Tb (blue line) and CoraFluor-1 freeacid (Tb) (red line), the concentrations of CDC20 protein and Tb were calculated by the absorbance values of CDC20 at a wavelength of 280nm and Tb at a wavelength of 340nm, respectively, and the labeling ratio was obtained. The labeling ratio CDC20:Tb was 1:1.5.
[0046] Example 3: Analysis of the interaction pattern characteristics of Halo Tag and small molecule ligand Halo Tag ligand-Tb using TG-FRET
[0047] 30 nM Halo Tag ligand-Tb and the serially diluted Halo Tag-Cy5 (0-960 nM) were added to the detection buffer (20 mM Tris, 50 mM NaCl, 0.1% Tween, pH 8.0) and incubated at room temperature for 1 hour before TG-FRET determination.
[0048] The fluorescence decay curve was obtained on the FLS1000 steady-state fluorescence spectrometer. The sample was pulsed with nitrogen laser (337.1 nm, 20 Hz). The wavelength of the Tb detection channel was 552 ± 8 nm, and the wavelength of the Cy5 detection channel was 665 ± 10 nm. The fluorescence decay curves of the donor and acceptor were collected and fitted by multi-channel scanning. The FRET probability and FRET efficiency (E) were calculated by the amplitude (A) and decay time (τ) of the fluorescence decay curve. FRET ) and FRET distance (r), and distinguish the FRET system as static FRET caused by concentration dependence or dynamic FRET caused by distance change.
[0049] Figure 3 A and Figure 3 B shows the fluorescence decay curves of the FRET donor channel (ChD) and the FRET acceptor channel (ChA). As can be seen from the figure, with the increase of Halo-Cy5 concentration, the fluorescence of the FRET donor Tb is quenched ( Figure 3 A), the fluorescence of the acceptor Cy5 is enhanced ( Figure 3 B), by counting Tb donors (I Tb ) and Cy5 receptor (I Cy5 ) is the sum of the number of photons in a certain time window (the integral of the fluorescence intensity in the time window from 0.1 to 0.8 ms after pulse excitation), and the FRET ratio and relative FRET ratio are calculated. The FRET ratio is calculated by using the fluorescence intensity of the Cy5-receptor Divided by the fluorescence intensity of the Tb-donor (Formula a), and the relative FRET ratio represents the relative change of the FRET ratio compared to the FRET ratio (FRET ratio (0)) when only the FRET donor is present (Formula b).
[0050]
[0051] relatively
[0052] Figure 3 C shows that with the increase of Halo Tag-Cy5 concentration (7.5nM-960nM), the FRET ratio and relative ratio also gradually increase. When the Halo Tag-Cy5 concentration is 240nM, the saturated binding platform is reached. The dissociation constant Kd=113nM is calculated using the single site-total binding fitting model in Prism8. This shows that Halo Tag has a strong binding affinity with its ligand.
[0053] The Tb-to-Cy5 FRET system was calculated according to formula c. Distance is E FRETWhen it is equal to 50%, the distance R0 between the donor and the acceptor is 5.5 nm.
[0054]
[0055] κ 2 is the orientation factor between the Tb and Cy5 fluorophore dipoles, is the quantum yield of the donor Tb, N A is Avogadro's constant, n is the refractive index, and the spectral overlap integral J is calculated according to formula d:
[0056]
[0057] Among them, I D (λ) is the emission intensity of the donor Tb after normalization of the emission spectrum area, ε A (λ) is the molar absorption coefficient of the acceptor Cy5, and λ is the wavelength.
[0058] Donor lifespan τ D When FRET occurs, the change in the actual distance r of the FRET system will cause the FRET donor fluorescence lifetime τ DA 、FRET acceptor fluorescence lifetime τ AD and FRET efficiency (E FRET ) changes.
[0059] Therefore, the present invention obtains the fluorescence lifetime of the donor and the acceptor in the presence of different concentrations of the acceptor by fitting the fluorescence decay curves of the donor and the acceptor, and then calculates the FRET distance r and FRET efficiency E between the donor and the acceptor. FRET Perform calculations.
[0060] All fluorescence decay curves were fitted with a multi-exponential intensity decay function (Equation e), among which the decay curve of Tb was fitted with a double exponential (τ D ,τ DA1 ) or a three-exponential function fit (τ D ,τ DA1 ,τ DA2 ), the decay curve of Cy5 adopts a three-exponential (τ D ,τ AD1 ,τ AD2 ) or four exponential function fitting (τ D ,τ AD1 ,τ AD2 ,τ AD3 ).
[0061]
[0062] Where I is the fluorescence intensity, τ i is the fluorescence lifetime, t is the decay time, A iis the amplitude corresponding to different fluorescence lifetimes, a i is the amplitude ratio of different fluorescence lifetimes.
[0063] For Tb donors, the average fluorescence lifetime < τ DA >(Formula f) Calculate the FRET distance r (Formula g) and FRET efficiency E of Tb-to-Cy5 FRET (Formula h).
[0064]
[0065] τ i is the fluorescence lifetime τ of FRET quenching DA1 ,τ DA2 .
[0066]
[0067] Where R0 is the Distance is E FRET The distance between the donor and the receptor when it is equal to 50%, τ D is the fluorescence lifetime of the donor when the donor exists alone, <τ DA > is the average fluorescence lifetime of the donor in the presence of the acceptor, <τ AD > is the average fluorescence lifetime of the acceptor in the presence of the donor. The FRET efficiency is calculated according to formula h
[0068]
[0069] For the Cy5 receptor, the average fluorescence lifetime < τ AD >(j) Calculate the FRET distance r (formula g) and FRET efficiency E of Tb-to-Cy5 FRET (Formula h), due to the excitation of the receptor and the FRET rate (k FRET-i ), amplitude A i Correction is required according to formula i.
[0070]
[0071]
[0072] According to the amplitude of the donor and acceptor channels (A DAi / A ADi ) Calculate the amplitude ratio of different FRET events occurring at the same receptor concentration (a DAi * / a ADi *)(Formula k and l), the probability of different FRET events is obtained. The interaction mode between Halo protein and its small molecule ligand is analyzed and calculated by calculating the average FRET efficiency, FRET distance and FRET probability. It can be seen that under different Halo-Cy5 concentrations, the average FRET distance r (r = 3-4nm) and FRET efficiency (E FRET =85%-95%) fluctuates within a small range, and the FRET distance and FRET efficiency do not change with the increase of Hao Tag concentration. At this time, the Tb-to-Cy5 FRET system belongs to concentration-dependent static FRET ( Figure 3 D / E).
[0073]
[0074]
[0075] The FRET probability, FRET efficiency and other information are plotted into a heat map to reflect the interaction between Halo Tag ligand-Tb and Halo Tag proteins of different concentrations (7.5nM-960nM). At the same Halo Tag-Cy5 concentration, the color depth represents the FRET efficiency, and the size of the color block represents the FRET probability of different FRET events. Figure 3 F) and FRET acceptor ( Figure 3 G) The analysis results are as follows: as the concentration of Halo Tag-Cy5 increases, the active site of Halo Tag is gradually occupied. When the concentration of Halo Tag-Cy5 is about 240nM, Halo Tag and Halo ligand-Tb reach saturation binding. When the concentration of Halo-Cy5 is low (7.5-30nM), due to the concentration effect, the FRET probability between Halo Tag protein and its ligand is low. As the concentration of FRET acceptor Halo-Cy5 increases, the FRET probability increases, but the FRET efficiency remains unchanged. The analysis results of the acceptor channel are similar to those of the donor channel: as the concentration of FRET acceptor Halo-Cy5 increases, the FRET probability increases, and the FRET efficiency and distance remain almost unchanged.
[0076] Example 4: Analysis of the interaction pattern characteristics between CDC20-Tb and small molecule ligand Apcin-Cy5 using TG-FRET
[0077] 15nM CDC20 and Apcin-Cy5 diluted in multiple ratios (Cmax = 5μM) were added to the detection buffer (20mM Tris, 50mM NaCl, 0.1% Tween, pH8.0) and incubated. TG-FRET measurement was performed after 1h of reaction at room temperature. The fluorescence decay curve was determined and fitted as described above, and all samples were set up as parallel samples.
[0078] Figure 4 A and Figure 4 B shows the fluorescence decay curves of the FRET donor channel (ChD) and the FRET acceptor channel (ChA). As the concentration of Apcin-Cy5 increases, the fluorescence of the FRET donor Tb is quenched ( Figure 4 A), the fluorescence of the acceptor Cy5 is enhanced ( Figure 4 B). By counting Tb donors (I Tb ) and Cy5 receptor (I Cy5 ) The sum of the number of photons in a certain time window (the integration of the fluorescence intensity in the time window from 0.2 to 2ms after pulse excitation) is used to calculate the FRET ratio and relative FRET ratio. The results of the FRET ratio and relative FRET ratio are shown in ( Figure 4 C), As the concentration of Apcin-Cy5 increases, the FRET ratio and relative FRET ratio also increase gradually.
[0079] The fluorescence decay curve fitting method of the donor and acceptor in the FRET system is the same as that in Example 3. The FRET efficiency ( Figure 4 E) and FRET distance ( Figure 4 D), FRET distance (r = 6 nm) and FRET efficiency (E) when the concentration of Apcin-Cy5 was between 0 and 1.2 μM. FRET =20%) remained almost unchanged, indicating that the Tb-to-Cy5 FRET system was concentration-dependent and belonged to static FRET. When the concentration of Apcin-Cy5 was greater than 2.4 μM, the FRET distance gradually decreased from 7 nm to 5.5 nm, and the FRET efficiency gradually increased from 20% to 50%. This was because the continued increase in the concentration of small molecules caused the binding orientation of CDC20 and Apcin-Cy5 to change. At this time, the Tb-to-Cy5 FRET system was distance-dependent and belonged to dynamic FRET.
[0080] As in Example 3, the information such as FRET probability and FRET efficiency is plotted as a heat map ( Figure 4 F and Figure 4G) reflects the interaction process between CDC20-Tb protein and Apcin-Cy5 small molecules at different concentrations. As the concentration of Apcin-Cy5 increases, the CDC20 active site is gradually occupied, and the FRET probability gradually increases. When the concentration of Apcin-Cy5 reaches 2.4 μM, the FRET probability is close to 100%.
[0081] In the present invention, the two model proteins have different characteristics when binding to their small molecule ligands. Compared with CDC20, Halo Tag has a smaller molecule, resulting in a closer distance between the FRET donor and the receptor, which makes the fluorescence decay of the donor Tb faster. It is also worth noting that in the process of CDC20 binding to ligands of different concentrations, changes in the relative orientation of the molecules occur, which may affect the relative conformation of the PROTAC ternary complex. Therefore, in the process of PROTAC drug development, the protein binding site and the ligand should be optimized according to the binding characteristics of the protein and the ligand, so as to provide the necessary conditions for obtaining a structurally stable target protein-PROTAC-E3 ligase ternary complex.
[0082] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit the protection scope of the present invention. For ordinary technicians in this field, other different forms of changes or modifications can be made based on the above descriptions and ideas. It is not necessary and impossible to list all the implementation methods here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.
Claims
1. A method for analyzing protein-small molecule interactions based on time-resolved fluorescence resonance energy transfer, characterized in that: The analytical method specifically comprises the following steps: (1) The PROTAC target protein was fluorescently labeled with FRET donor and acceptor fluorophores, and the protein was purified and characterized by spectral properties; the target proteins were Halo Tag and E3 ubiquitin ligase CDC20; the PROTAC target protein Halo Tag was labeled with FRET acceptor fluorophore Cy5-NHS ester, and the E3 ubiquitin ligase CDC20 protein was labeled with FRET donor fluorophore CoraFluor-1 free acidTb; (2) The fluorescently labeled PROTAC mimics the target protein and the fluorescent derivatization reagent of its small molecule ligand are co-incubated to form a FRET system; the fluorescence donor is used for excitation, the fluorescence decay curve of the donor and the acceptor in the FRET system is collected, and the fluorescence decay curve is fitted; (3) Analyze spectral data, calculate the binding parameters of protein-small molecule interactions, and obtain the results of protein-small molecule interaction pattern analysis; The analysis of spectral data is to use multi-channel scanning, measure the fluorescence decay curve of the donor and acceptor in the FRET system, count the total number of photons of the donor and acceptor in a certain time window, and calculate the FRET ratio by the ratio of the fluorescence intensity of the donor and acceptor; use the unit site-total binding fitting model in Prism8 to calculate the dissociation constant Kd; and calculate the FRET efficiency in the presence of different concentrations of acceptors by fitting the fluorescence decay curves of the donor and acceptor. and FRET distance Changes in protein-small molecule interaction patterns; When there are different concentrations of fluorescently labeled PROTAC mimic target proteins, the FRET distance and FRET efficiency do not change significantly with the increase in the concentration of the simulated target protein, that is, the change in FRET distance is within ±5%, and the change in FRET efficiency is within ±10%. At this time, FRET exhibits ligand concentration-dependent static FRET with unchanged FRET efficiency and FRET distance; When there is a low concentration of fluorescently labeled small molecules, the FRET distance and FRET efficiency remain almost unchanged. At this time, the FRET system exhibits concentration-dependent static FRET. As the concentration of small molecules increases, the FRET distance shows a significant downward trend, while the FRET efficiency shows a significant upward trend. At this time, the FRET system exhibits distance-dependent dynamic FRET with changes in FRET distance and efficiency.
2. The protein-small molecule interaction analysis method based on time-resolved fluorescence resonance energy transfer according to claim 1, characterized in that: In the step (2), the fluorescent derivatization reagents of the small molecule ligands of the PROTAC mimicking target protein Halo Tag and E3 ubiquitin ligase CDC20 protein are Halo Tag ligand-Tb and Apcin-Cy5, respectively.
3. The protein-small molecule interaction analysis method based on time-resolved fluorescence resonance energy transfer according to claim 1, characterized in that: The fluorescence decay curve is fitted using a multi-exponential intensity decay function: ; Where I is the fluorescence intensity, is the fluorescence lifetime, t is the decay time, is the amplitude ratio of different fluorescence lifetimes.
4. The protein-small molecule interaction analysis method based on time-resolved fluorescence resonance energy transfer according to claim 1, characterized in that: The calculation formula of the FRET distance r is as follows: Where R0 is the Förster distance of the FRET system, When the distance between the donor and the receptor is equal to 50%, is the fluorescence lifetime of the donor when the donor exists alone, is the average fluorescence lifetime of the donor in the presence of the acceptor, is the average fluorescence lifetime of the acceptor in the presence of the donor.
5. The protein-small molecule interaction analysis method based on time-resolved fluorescence resonance energy transfer according to claim 4, characterized in that: The FRET efficiency The calculation formula is as follows: 。
